Trial Profile
Randomized Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer (Merrimack Pharmaceuticals Inc.)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Seribantumab (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms SHERBOC
- Sponsors Elevation Oncology; Merrimack Pharmaceuticals
- 07 Nov 2018 Status changed from recruiting to discontinued, as reported in the Merrimack Pharmaceuticals media release.
- 07 Nov 2018 According to a Merrimack Pharmaceuticals media release, based on the results of the interim analysis of Phase 2 SHERLOC study the company has decided to discontinue development of all ongoing MM-121 programs, including the SHERBOC study.
- 26 Feb 2018 According to a Merrimack Pharmaceuticals media release, the first patient has been dosed in this study at the UF Health Cancer Center at Orlando Health in the United States.